China, EU firms ink pact for new HPV vaccine

A vaccine that may prevent infection from up to 20 types of viruses, which could lead to cervical cancer, may come into being through a Sino-European collaboration.

Hangzhou-based YangSheng-Tang Group's Xiamen Innovax Biotech Co Ltd signed a global alliance partnership agreement with British pharmaceutical giant GlaxoSmithKline (GSK) to develop a next-generation vaccine against the human papillomavirus (HPV) last month.

It was the first time a Chinese vaccine company had entered into partnership with a world-leading drug conglomerate to jointly develop and ultimately commercialize a vaccine that benefits women globally.